TC BIOPHARM (HOLDINGS) PLC

(TCBP)
  Report
End-of-day quote Nasdaq  -  2022-08-04
0.3780 USD   +0.69%
07/29European ADRs Move Higher in Friday Trading
MT
07/13Advancing cell therapies - γδ T cells and the combination factor
AQ
06/07TC Biopharm Completes $4 Million Stock Sale
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
0.3498 0.345 0.365 0.3754 0.378 Last
548459 349288 2497099 454637 282938 Volume
-3.00% -1.37% +5.80% +2.85% +0.69% Change
Estimated financial data (e) (USD)
Sales 2022 1,60 M - -
Net income 2022 -15,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,76x
Yield 2022 -
Sales 2023
Net income 2023
Net Debt 2023
P/E ratio 2023
Yield 2023
Capitalization 14,4 M 14,4 M -
Capi. / Sales 2022 8,99x
EV / Sales 2023
Nbr of Employees 76
Free-Float 40,9%
More Financials
Company
TC BioPharm Limited is a clinical-stage cell therapy company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows Company's to design specific therapies to treat a range of cancers and infectious diseases with off the shelf... 
More about the company
All news about TC BIOPHARM (HOLDINGS) PLC
07/29European ADRs Move Higher in Friday Trading
MT
07/13Advancing cell therapies - γδ T cells and the combination factor
AQ
06/07TC Biopharm Completes $4 Million Stock Sale
MT
06/03Top Premarket Decliners
MT
06/03TC BioPharm Prices Offering at $0.40/ADS
MT
05/26Top Premarket Gainers
MT
05/18TC Biopharm Announces Formation of Scientific Advisory Board
CI
05/17European ADRs Move Higher in Tuesday Trading
MT
05/16European ADRs Move Higher in Monday Trading
MT
05/13TC Biopharm Plc Reports Earnings Results for the Full Year Ended December 31, 2021
CI
05/13European ADRs Move Higher in Friday Trading
MT
05/13TC Biopharm Plc Auditor Raises 'Going Concern' Doubt
CI
05/12European ADRs Decline in Thursday Trading
MT
05/05European ADRs Decline in Thursday Trading
MT
04/06TC Biopharm Secures UK Trademark for CryoTC Cell Freezing Process
MT
More news
News in other languages on TC BIOPHARM (HOLDINGS) PLC
07/29Les ADR européens sont en hausse vendredi
06/07TC Biopharm conclut une vente d'actions de 4 millions de dollars
06/03TC BioPharm fixe le prix de son offre à 0,40 $/ADS
05/18TC Biopharm annonce la formation d'un conseil consultatif scientifique
05/17Les ADR européens sont en hausse mardi
More news
Analyst Recommendations on TC BIOPHARM (HOLDINGS) PLC
More recommendations
Chart TC BIOPHARM (HOLDINGS) PLC
Duration : Period :
TC Biopharm (Holdings) Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,38 $
Average target price 5,00 $
Spread / Average Target 1 223%
EPS Revisions
Managers and Directors
Bryan Kobel Chief Executive Officer & Director
Martin Edward Thorp Chief Financial Officer & Director
Michael Leek Executive Chairman
Angela Scott Chief Operating Officer
Mark L. Bonyhadi Independent Director
Sector and Competitors
1st jan.Capi. (M$)
TC BIOPHARM (HOLDINGS) PLC0.00%14
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.80%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235